Toxicological Profiling for Breast Cancer Drugs
Several novel therapies have been approved for the treatment of breast cancer, and some of these therapies exhibit toxicity profiles that differ significantly from conventional anti-tumor treatments. Alfa Cytology offers toxicological profiling services specifically designed for breast cancer drugs to address diverse mechanisms of toxicity.
Overview of Toxicological Profiling for Breast Cancer Drugs
While most research on new drug evaluations focuses on their biological activity, it is equally important to consider drug toxicity. There have been reports on a novel benzimidazole derivative, and by investigating the compound's toxicological behavior, it has been found to exhibit minimal cytotoxicity towards normal cells, with no significant mortality or morbidity, and selectively induce apoptosis in breast cancer cells.
Fig. 1. Toxicological profile of BMPE both in vitro and in vivo. (Farrag EK, et al., 2023)
Our Services
New therapies for breast cancer may give rise to adverse events, some of which differ significantly from the well-defined and often predictable side effects associated with chemotherapy. Alfa Cytology offers experimental testing of various toxicities to facilitate your exploration of a drug's toxicological characteristics. Through our services, we enable you to assess the potential safety and toxicity of candidate drugs, thereby expediting the drug development process.
In Vitro Toxicology Services
Assess the toxicity effects of breast cancer drugs on breast cancer cell lines or other relevant cells. We offer in vitro toxicity testing services including, but not limited to, the following cytotoxicity assays. The in vitro toxicology portfolio covers several assays for screening of cytotoxicity, genotoxicity, and cardiotoxicity
- MTT assay
- Apoptosis detection
- Cell proliferation inhibition assays
In Vivo Toxicology Services
Utilize appropriate breast cancer animal models to evaluate the toxicity effects of the drugs. These experiments may involve the measurement of physiological, biochemical, and histological parameters in animals, as well as the assessment of drug effects on different organs and tissues.
- Cardiotoxicity
- Pulmonary toxicity
- Gastrointestinal and skin toxicity
- Haematological toxicity
- Hepatotoxicity
Immunotoxicology Testing
Assess the impact of breast cancer drugs on the immune system. Immunotoxicology testing typically starts with a screening study on immune function using a standard protocol. These assays may involve lymphocyte function tests, immunohistochemistry, and immunohistology.
- Evaluation of innate immunity
- Evaluation of cell–mediated immunity
- Evaluation of humoral-mediated immunity
- Immunopathology
Developmental and Reproductive Toxicity Assays
We have developed a range of techniques and testing regimes to Evaluate the toxicity effects of breast cancer drugs on the reproductive system and embryo/fetal development. These assays continue to be used to identify and de-risk potential pharmaceuticals that have a teratogenic or reproductive toxicity.
- Modified one-generation studies
- Reproductive studies
- Prenatal developmental toxicity studies
Exploration of Different Drugs Toxicity Profile
Toxicological features and factors triggering adverse events play a significant role in the context of breast cancer and its treatment with anticancer drugs. Assessing these toxicity characteristics can be an intriguing aspect when considering personalized therapies. We offer customized toxicological testing services for various types of breast cancer drugs.
Contact Us
Alfa Cytology combines scientific expertise, cutting-edge technologies, and a dedication to safety to provide you with reliable toxicological profiling services. Contact us to discuss your toxicological profiling needs and how we can assist you in advancing your breast cancer drug development program.
Reference
- Farrag EK, et al. Toxicological profiling of a de novo synthesized benzimidazole derivative with potent and selective proapoptotic potentials against breast cancer. Food and Chemical Toxicology. 2023, 180: 114049.